

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	MicroRNA-155 (miR-155)	<p><i>In vitro</i> and mouse studies suggest inhibiting miR-155 could help treat breast cancer 1 early onset (BRCA1)-deficient breast cancers. In cell lines lacking BRCA1 or expressing mutant BRCA1, compared with those expressing wild-type BRCA1, miR-155 was upregulated. In mice, BRCA1-deficient tumor cells expressing miR-155 led to greater tumor growth than BRCA1-deficient tumor cells with miR-155 knockdown. Next steps include testing miR-155 inhibition in BRCA1-mutant breast cancers.</p> <p>SciBX 4(39); doi:10.1038/scibx.2011.1085 Published online Oct. 6, 2011</p>	Patent status not applicable; unavailable for licensing	<p>Chang, S. <i>et al. Nat. Med.</i>; published online Sept. 25, 2011; doi:10.1038/nm.2459 Contact: Shyam K. Sharan, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia e-mail: sharans@mail.nih.gov</p>